Paul Tudor Jones Ligand Pharmaceuticals Inc Transaction History
Tudor Investment Corp Et Al
- $200 Billion
- Q3 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 15,750,000 shares of LGND stock, worth $3.16 Billion. This represents 1.4% of its overall portfolio holdings.
Number of Shares
15,750,000Holding current value
$3.16 Billion% of portfolio
1.4%Shares
18 transactions
Others Institutions Holding LGND
# of Institutions
343Shares Held
36.7MCall Options Held
19KPut Options Held
11.5K-
Black Rock Inc. New York, NY2.87MShares$577 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.08MShares$417 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.04MShares$209 Million0.09% of portfolio
-
Macquarie Group LTD Australia, C3752KShares$151 Million0.16% of portfolio
-
State Street Corp Boston, MA749KShares$151 Million0.0% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $3.39B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...